IL-32α is involved in the progression of hepatocellular carcinoma, but the overexpression of IL-32α enhances natural killer cell-mediated killing by upregulating the expression of Fas and UL16 binding protein 2 (ULBP2) in human chronic myelogenous leukemia cells, exerting an anti-cancer effect43. Here, FAS is linked to chronic myelogenous leukemia, BCR-ABL1 positive.